4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Primary Soft Tissue Sarcoma of the Heart: An Emerging Chapter in Cardio-Oncology

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Primary malignant cardiac tumors are rare, with a prevalence of about 0.01% among all cancer histotypes. At least 60% of them are primary soft tissue sarcomas of the heart (pSTS-h) that represent almost 1% of all STSs. The cardiac site of origin is the best way to classify pSTS-h as it is directly linked to the surgical approach for cancer removal. Indeed, histological differentiation should integrate the classification to provide insights into prognosis and survival expectancy of the patients. The prognosis of pSTS-h is severe and mostly influenced by the primary localization of the tumor, the difficulty in achieving complete surgical and pharmacological eradication, and the aggressive biological features of malignant cells. This review aims to provide a detailed literature overview of the most relevant issues on primary soft tissue sarcoma of the heart and highlight potential diagnostic and therapeutic future perspectives.

          Related collections

          Most cited references103

          • Record: found
          • Abstract: found
          • Article: not found

          Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

          A non-randomised, phase 2 study showed activity and tolerability of eribulin in advanced or metastatic soft-tissue sarcoma. In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine (an active control).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

            This multicenter study, to our knowledge, is the first phase III trial to compare trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy with an anthracycline and at least one additional systemic regimen.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.

              Vascular endothelial growth factors (VEGFs) regulate vascular development, angiogenesis and lymphangiogenesis by binding to a number of receptors. VEGFR-1 is required for the recruitment of haematopoietic stem cells and the migration of monocytes and macrophages, VEGFR-2 regulates vascular endothelial function and VEGFR-3 regulates lymphatic endothelial cell function. Over the last decade, considerable progress has been made in delineating the VEGFR-2 specific intracellular signalling cascades leading to proliferation, migration, survival and increased permeability, each of which contributes to the angiogenic response. Furthermore, therapeutic inhibition of VEGFR-2 action is now having an impact in the clinic for the treatment of a number of diseases.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Biomedicines
                Biomedicines
                biomedicines
                Biomedicines
                MDPI
                2227-9059
                03 July 2021
                July 2021
                : 9
                : 7
                : 774
                Affiliations
                [1 ]Cardiology Department, Hospital “F. Perinei”, 70022 Altamura, Italy
                [2 ]Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, 70124 Bari, Italy; sergimariachiara@ 123456gmail.com (M.C.S.); marica.gentile@ 123456libero.it (M.G.); camillo.porta@ 123456uniba.it (C.P.); marco.tucci@ 123456uniba.it (M.T.)
                [3 ]Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy; matteo.cameli@ 123456yahoo.com
                [4 ]Cardiology Institute of Rio Grande do Sul, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre 90050-170, Brazil; marcelohaertel@ 123456gmail.com
                [5 ]Cardiology Section, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, 70124 Bari, Italy; marcomatteo.ciccone@ 123456uniba.it
                Author notes
                [* ]Correspondence: piero.sc@ 123456hotmail.it ; Tel.: +39-0803108286
                [†]

                Co-Last Authors.

                Author information
                https://orcid.org/0000-0003-0471-0053
                https://orcid.org/0000-0002-3093-6841
                https://orcid.org/0000-0003-3872-8964
                https://orcid.org/0000-0002-3314-9712
                https://orcid.org/0000-0003-4008-4897
                Article
                biomedicines-09-00774
                10.3390/biomedicines9070774
                8301302
                34356838
                bb510cda-82f6-49b4-a9f0-0977f61ba852
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 05 June 2021
                : 02 July 2021
                Categories
                Review

                cardiac sarcoma,diagnosis,molecular diagnosis,treatment,cardio-oncology

                Comments

                Comment on this article